DrugDashboards

Acetaminophen and Ibuprofen

Acetaminophen and Ibuprofen · ACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1 · Tablet · Oral · Rugby Laboratories

NDC 00536-1376-36 · 36 TABLET in 1 BOTTLE · ANDA · View full market →

The short version

9 companies supply this market — a reasonable cushion if one runs into trouble. The price has held steady around $0.0844 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.05$0.1$0.15Mar 2024Sep 2026$0.0844
28 price points · per EA · held since Invalid DateSource: CMS NADAC

Estimated fill cost

#30 count
$2.53
#90 count
$7.60

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$89
15 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

0Low risk

Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for acetaminophen and ibuprofen (oral solid) in the next 90 days

price up 19% YoY · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program · Opioid Analgesic REMS Shared System REMS

Regulatory

Application
ANDA216592
TE code
Approval date
Jul 13, 2023
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Acetaminophen and Ibuprofen (Tablet)

LabelerStrengthFirst seenLast seen
Granules Pharmaceuticals Inc.ACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1Jul 15, 2026Sep 3, 2026
CvsACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1Jul 15, 2026Sep 2, 2026
CvsACETAMINOPHEN 1 mg/1; IBUPROFEN 125 mg/1Jul 15, 2026Sep 2, 2026
CvsIBUPROFEN 125 mg/1; ACETAMINOPHEN 250 mg/1Aug 26, 2026Sep 2, 2026
Family DollarACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1Jul 15, 2026Sep 2, 2026
Granules India LimitedACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1Jul 15, 2026Sep 2, 2026
Granules Usa, Inc.ACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1Jul 15, 2026Sep 2, 2026
LEADER/ Cardinal Health 110, Inc.ACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1Jul 15, 2026Sep 2, 2026
Rugby LaboratoriesACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1Jul 15, 2026Sep 2, 2026
Wal-Mart Stores Inc.IBUPROFEN 125 mg/1; ACETAMINOPHEN 250 mg/1Aug 26, 2026Sep 2, 2026
WalgreensACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1Jul 15, 2026Sep 2, 2026
CvsIBUPROFEN 250 mg/1; ACETAMINOPHEN 125 mg/1Jul 22, 2026Aug 19, 2026
Wal-Mart Stores Inc.IBUPROFEN 250 mg/1; ACETAMINOPHEN 125 mg/1Jul 22, 2026Aug 19, 2026
Wal-Mart Stores Inc.ACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Acetaminophen and Ibuprofen — NDC 00536-1376-36," retrieved September 3, 2026, https://drugdashboards.com/drug/00536137636.

Free to cite with attribution — see how the data is put together.